MLV & Co Expects Positive News from Galectin Therapeutics

In a report published Tuesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $20.00 price target on

. In the report, MLV & Co noted, “Albeit from 8 patients, an abundance of data support the safety and positive effects of GR-MD-02 on the major pathological processes observed in NASH. Next steps include dosing at 4mg/kg, adding FibroScan, an FDA-approved ultrasonic measure of liver tissue elasticity, to cohort 2 protocol. We continue to expect positive results in cohort 2 (expected Jul-Aug 2014).” Galectin Therapeutics closed on Monday at $15.31.